deltatrials
Completed PHASE3 NCT01049347

Amitriptyline and Paroxetine Treatment of Major Depression

Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients

Sponsor: Central Institute of Mental Health, Mannheim

Conditions Unipolar Depression
Interventions amitriptyline paroxetine
Updated 6 times since 2017 Last updated: Jan 30, 2024 Started: Oct 31, 1997 Primary completion: May 31, 2000 Completion: May 31, 2000

A PHASE3 clinical study on Unipolar Depression, this trial is completed. The trial is conducted by Central Institute of Mental Health, Mannheim and has accumulated 6 data snapshots since 1997. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Feb 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Oct 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Central Institute of Mental Health, Mannheim
Data source: Central Institute of Mental Health, Mannheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Mannheim, Germany